Zero ad trackers.We never sell your data.Healthcare professional?Clinician Resources
Home/Rare Diseases/Hemophilia B

Blood & Immune

Hemophilia B Clinical Trials and Treatments

Also called Factor IX deficiency, Christmas disease, X-linked hemophilia, Hemophilia Type B, Haemophilia B

Hemophilia B is an X-linked recessive inherited bleeding disorder caused by deficiency or dysfunction of clotting factor IX (Christmas factor). Pathophysiology involves reduced or abnormal factor IX protein affecting the intrinsic tenase complex essential for coagulation amplification. Clinically, hemophilia B is indistinguishable from hemophilia A, with manifestations strictly dependent on factor IX activity levels.

In plain words, hemophilia B is an inherited bleeding disorder where a clotting protein called factor IX is missing or does not work well. Without it, blood does not clot properly, so people bruise easily and may bleed into joints and muscles.

Get an email when new Hemophilia B trials open or the FDA decides. Get alerts

Hemophilia B

Where treatments stand, from ClinicalTrials.gov and FDA labels

FDA review0

No decision pending. FDA calendar

FDA-approved medicines11

Alhemo · Hemgenix · Hympavzi · Qfitlia · Alprolix · 6 more

Hemophilia B has 11 FDA-approved medicines, 30 open or active clinical trials, and no pending FDA decision.

Labels checked October 21, 2026. Corticosteroids and immune globulins count once each.Download the data

Each date is the day a change was posted. Open an item to see where things stand now.

More about Hemophilia B

Severe disease (<1% factor activity) causes spontaneous bleeding into joints and muscles without provocation; moderate disease (1-5% activity) causes bleeding with minor trauma and progressive joint disease; mild disease (5-40% activity) causes bleeding only with significant trauma or surgery. Joint bleeds (hemarthrosis) cause hemarthropathy with chronic pain and joint destruction if untreated. Spontaneous intracranial hemorrhage and other serious bleeding episodes represent major morbidity.

Keep reading about Hemophilia B

Diagnosis requires factor IX activity assay showing reduced levels. The condition accounts for approximately 15-20% of all hemophilia cases. Factor IX deficiency results in the same bleeding phenotype as factor VIII deficiency, distinguishable only by specific factor assays. Most affected males have severe disease.

What are the symptoms of Hemophilia B?

These are common symptoms of Hemophilia B, and how strong they are varies from person to person.

  • Easy bruising and bleeding
  • Hemarthrosis (joint bleeds) causing pain and swelling
  • Muscle hematomas
  • Spontaneous bleeding in severe forms
  • Bleeding after trauma or surgery
  • Oral and GI bleeding

Who gets Hemophilia B?

Affects males predominantly with estimated prevalence of 1 in 25,000-33,000 males worldwide. Very rare in females, occurring only in special circumstances. Hemizygous males have severe disease; heterozygous females rarely develop symptoms.

All ethnic and racial groups affected with similar incidence. No significant geographic variation in prevalence identified. Approximately 20% of hemophilia B cases represent de novo mutations. Family history crucial for carrier identification and genetic counseling.

Next steps: find trials you might fitcompare treatmentsget help payingget alerts

Which medicines are FDA-approved for Hemophilia B?

There are currently 11 FDA-approved medications for Hemophilia B.

concizumab
Novo Nordisk
Search
etranacogene dezaparvovec
CSL Behring / uniQure
Official site
marstacimab
Pfizer
Search
fitusiran
Sanofi / Alnylam
Search
Alprolix
coagulation factor ix (recombinant), fc fusion protein (eftrenonacog alfa)
BeneFIX
coagulation factor ix (recombinant)
Feiba
anti-inhibitor coagulant complex
Idelvion
coagulation factor ix (recombinant), albumin fusion protein (albutrepenonacog alfa)
NovoSeven RT
coagulation factor viia (recombinant) (eptacog alfa)
Profilnine
factor ix complex (human)
Rebinyn
coagulation factor ix (recombinant), glycopegylated (nonacog beta pegol)

Source: openFDA drug labeling data. This list may not include all treatments. Always consult your doctor.

How to get help paying for Hemophilia B treatment

Charity funds and drugmaker programs for Hemophilia B, checked at the source.

Which insurance do you have? Pick one to see what fits. Tap it again to clear.
Your insurance
Charity funds
  • From a charity · Hemophilia Federation of America
    Helping Hands Program fund
    Open

    Pays for: Emergency living expenses ($250 prepaid card, once per year; referral through HTC or member organization; does not cover medical bills, copays or premiums), up to $250 per year.

    The foundation says: “The Helping Hands program is now open on a limited basis for 2026. Due to funding constraints, a maximum of 20 requests will be approved…”
  • From a charity · TotalAssist (formerly PAN Foundation)
    Hemophilia fund
    Open

    Pays for: Out-of-pocket costs for approved medications, up to $12,500 per year. Requires health insurance (any kind).

  • From a charity · The Assistance Fund
    Hemophilia fund
    Waitlist

    Pays for: Copays, coinsurance, deductibles and other health-related expenses.

Status as each foundation showed it on November 16, 2026.

Every program and fund for Hemophilia B, by insurance →

Side effects people have reported to the FDA

Side effects people have reported to the FDA

Real-world side effect reports from the FDA Adverse Event Reporting System (FAERS). Includes both FDA-approved drugs and investigational therapies from active clinical trials. Click any drug to see what patients reported.

Loading side effect data...

Diagnosis and genetic testing

Genetic testing for Hemophilia B

Genetic testing can confirm a diagnosis, guide treatment decisions, and identify family members who may be at risk.

Finding labs...

Trusted Hemophilia B resources

Reputable organizations and medical references for learning more about Hemophilia B, including disease registries, foundation resources, and clinical guidelines.

Active clinical trials for Hemophilia B

Use this Hemophilia B clinical trial finder to see the 15 studies recruiting patients and 5 not yet recruiting in the United States and worldwide, with eligibility criteria in plain English. Of these, 13 test a treatment and 7 are observational studies or registries; each card says which. Every trial comes from ClinicalTrials.gov.

Jump to the trial list, the site map or the pipeline timeline.

Note: Trial recruitment statuses on ClinicalTrials.gov may not immediately reflect recent FDA decisions, sponsor announcements, or enrollment changes. Always confirm a trial's current status directly with the study coordinator before making plans.

30 active trials worldwide
Filter:
Sort:
RecruitingTreatment trialPhase 3Recently updatedNCT05568719

Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B Respectively

Intervention: Testing of hepatic AAV Vector integration

Sponsor: Pfizer

A study to learn about the long-term safety and efficacy of giroctocogene fitelparvovec or fidanacogene elaparvovec in patients with hemophilia A or hemophilia B respectively, who have received treatment through prior participation in a Pfizer-sponsored clinical trial. Data colle...

Ages 18 Years+
Started Dec 2022Updated yesterdayEst. Feb 2040 (~13y 3m)
Not yet recruitingTreatment trialRecently updatedNCT07916467

Safety of Intraosseous Anaesthesia in Children With Haemophilia

Intervention: Intraosseous Anaesthesia

Sponsor: Ankara Yildirim Beyazıt University

Effective local anaesthesia is essential for safe and comfortable dental treatment in children with haemophilia. However, conventional nerve block techniques, particularly inferior alveolar nerve block, carry an increased risk of bleeding and haematoma formation because of their ...

Ages 4 Years to 12 Years1 location
Expected to start Jan 2027Updated 2 weeks agoEst. Jul 2027 (~7 months)
Not yet recruitingTreatment trialPhase 1Recently updatedNCT03961243

Lentiviral FIX Gene Therapy

Intervention: YUVA-GT-F901

Sponsor: Shenzhen Geno-Immune Medical Institute

This study is a Phase I trial using an advanced lentiviral vector to deliver a functional gene for human clotting factor IX into patients with hemophilia B, to evaluate the safety and efficacy of infusion of lentiviral gene modified autologous stem cells in patients.

Ages 2 Years to 65 Years1 location
Expected to start Jun 2027Updated 2 weeks agoEst. May 2028 (~1y 6m)
RecruitingTreatment trialPhase 3Recently updatedNCT05145127

Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors

Intervention: PF-06741086

Sponsor: Pfizer

Study B7841007 is an open-label extension study to assess the long-term safety, tolerability, and efficacy of prophylaxis treatment with marstacimab in participants who did not require "Early Termination" from the Phase 3 Study B7841005 and from the Phase 3 Study B7841008.

Ages 1 Year to 74 Years
Started Nov 2021Updated 3 weeks agoEst. Jul 2030 (~3y 8m)
Not yet recruitingObservational study, no treatment givenRecently updatedNCT05932914

Liver Biopsy Following Gene Therapy For Hemophilia

Intervention: Liver Biopsy

Sponsor: St. Jude Children's Research Hospital

This observational study will obtain liver biopsy samples and evaluate the long-term effect of adeno-associated virus (AAV)-mediated gene therapy on the liver tissue in adult patients with hemophilia A or hemophilia B who have previously been treated with a factor VIII or factor ...

Ages 18 Years to 80 Years1 location
Expected to start Nov 2026Updated 3 weeks agoEst. Jan 2030 (~3y 2m)
Find Hemophilia B trials near you, ranked by distance →
Active trial locations77 cities in the US
A study site. Select it to see its trials and get directions. Several sites close together. Select the number to zoom in.
+69 more

Trial Pipeline

Jan 2021 to Nov 2031
2021
2023
2025
2027
2029
2031
now
Phase 1
Phase 3
Phase 4
Observational
Observational
RecruitingNot yet recruitingDelayed startTodayHover a bar for trial details

Read more about Hemophilia B trials

Need help understanding these trials?
Answers with sources, in plain English
Start withor ask
Run a Hemophilia B foundation or patient group?
You can put this live trial list on your own website. It updates itself, and it's free.
Get the embed code →

Data from ClinicalTrials.gov, U.S. National Library of Medicine.
Always talk to your doctor before considering a clinical trial.

Hemophilia B patient communities

Facebook groups, Reddit communities and YouTube channels where Hemophilia B patients, caregivers and advocacy groups talk.

Hemophilia B news and guides

Trial Friend articles about Hemophilia B, newest first

Companies developing Hemophilia B treatments

Drugmakers that list Hemophilia B in their rare disease portfolio, with makers of its treatments first.

Questions people ask about Hemophilia B